Skip to Content

Single-Dose Ad26.COV2.S Effective Against COVID-19

FRIDAY, April 23, 2021 -- A single dose of human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 spike protein (Ad26.COV2.S) protects against moderate- to severe-critical and severe-critical COVID-19, according to a study published online April 21 in the New England Journal of Medicine.

Jerald Sadoff, M.D., from Janssen Vaccines and Prevention in Leiden, Netherlands, and colleagues randomly assigned adults to receive a single dose of either Ad26.COV2.S or placebo in an international randomized trial (19,630 received Ad26.COV2.S and 19,691 received placebo in the per-protocol population) to examine efficacy against moderate- to severe-critical COVID-19.

The researchers found that Ad26.COV2.S protected against moderate- to severe-critical COVID-19 with onset at least 14 days after administration (efficacy, 66.9 percent) and at least 28 days after administration (66.1 percent). Higher vaccine efficacy was seen against severe-critical COVID-19 (76.7 and 85.4 percent for onset at ≥14 days and at ≥28 days, respectively). Vaccine efficacy was 52.0 and 64.0 percent, respectively, against moderate- to severe-critical COVID-19 with onset at ≥14 days and at ≥28 days after administration among cases in South Africa; 94.5 percent of these cases had the 20H/501Y.V2 variant. Efficacy against severe-critical COVID-19 was 73.1 and 81.7 percent, respectively. Compared with placebo, reactogenicity was higher with Ad26.COV2.S, but was mainly mild to moderate and transient. Between the groups, the incidence of serious adverse events was balanced. Three and 16 deaths occurred in the vaccine and placebo groups, respectively (none and five, respectively, were COVID-19-related).

"The single-dose schedule and favorable storage conditions of this vaccine provide major advantages in its deployment and effect worldwide," the authors write.

The study was funded by Janssen Research and Development, an affiliate of Janssen Vaccines and Prevention and part of the Janssen pharmaceutical companies of Johnson & Johnson.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

Efficacy of BNT162b2 mRNA COVID-19 Vaccine Lower in Patients With CLL

THURSDAY, May 6, 2021 -- The BNT162b2 mRNA COVID-19 vaccine has lower efficacy among patients with chronic lymphocytic leukemia (CLL) and induces lower neutralizing antibody...

HPV Vaccination Rates Low for Young Adults

THURSDAY, May 6, 2021 -- Self-reported human papillomavirus (HPV) vaccination rates for young adults, whether for receipt of a dose at any age or between ages 18 and 21 years, are...

Canada Approves Pfizer COVID-19 Vaccine for Children Ages 12 to 15

WEDNESDAY, May 5, 2021 -- The Pfizer COVID-19 vaccine has been approved by Canadian health officials for use in children ages 12 to 15 years. It was already authorized for anyone...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.